[go: up one dir, main page]

KR850700216A - 활성성분을 용해시키기 위한 방법 및 이로부터 얻어진 제약 조성물 - Google Patents

활성성분을 용해시키기 위한 방법 및 이로부터 얻어진 제약 조성물

Info

Publication number
KR850700216A
KR850700216A KR1019850700302A KR850700302A KR850700216A KR 850700216 A KR850700216 A KR 850700216A KR 1019850700302 A KR1019850700302 A KR 1019850700302A KR 850700302 A KR850700302 A KR 850700302A KR 850700216 A KR850700216 A KR 850700216A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
active ingredient
composition according
dissolving
composition obtained
Prior art date
Application number
KR1019850700302A
Other languages
English (en)
Other versions
KR930000029B1 (ko
Inventor
제롬 꼬르비에르
Original Assignee
제롬 꼬르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제롬 꼬르비에르 filed Critical 제롬 꼬르비에르
Publication of KR850700216A publication Critical patent/KR850700216A/ko
Application granted granted Critical
Publication of KR930000029B1 publication Critical patent/KR930000029B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

내용 없음

Description

활성성분을 용해시키기 위한 방법 및 이로부터 얻어진 제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 활성성분을 300내지 700의 분자량을 갖는 에틸렌글리콜의 하나 또는 여러가지 중합체에 처음으로 용해시키고, 그다음 이용액을 사전에 pH같이 조정된 수용성매질에 가함을 특징으로 하는 소수성 유기화합물을 용해시키는 방법.
  2. 제1항에 있어서, 유기상이 또한 방부제, 안정제, 향미제, 착색 물질 또는 감미제를 함용함을 특징으로 하는 방법.
  3. 제1항에 있어서, 수용액상은 pH, 무기염, 방부제 및/또는 다른 제약학적―활성화합물을 위해 고정된 값을 결정하기 위한 방법으로 가해짐을 특징으로 하는 방법.
  4. 비경구, 경구, 근육내 또는 피부경로로 투여하여 사용하기 적합한 제1항의 방법에 의해 또는 제1항의 방법으로 얻어진 제약 조성물.
  5. 제4항에 있어서, 눈에 사용하기 위한 눈점적약 또는 용액의 형태임을 특징으로 하는 제약 조성물.
  6. 제4 또는 5항에 있어서, 활성성분의 퍼센트가 0.1내지 25%의 범위임을 특징으로 하는 제약 조성물.
  7. 제4 또는 5항에 있어서, 활성성분이 인도메타신임을 특징으로 하는 제약 조성물.
  8. 제7항에 있어서, 단위투여량당 인도메타신의 퍼센트가 0.1내지 1%의 범위임을 특징으로 하는 제약 조성물.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019850700302A 1984-03-14 1985-03-12 N-아실 인돌류 활성성분의 용해방법 KR930000029B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1279/84 1984-03-14
CH127984 1984-03-14
PCT/FR1985/000050 WO1985004106A1 (fr) 1984-03-14 1985-03-12 Ppocede de solubilisation de principes actifs et compositions pharmaceutiques ainsi obtenues

Publications (2)

Publication Number Publication Date
KR850700216A true KR850700216A (ko) 1985-12-26
KR930000029B1 KR930000029B1 (ko) 1993-01-06

Family

ID=4206704

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850700302A KR930000029B1 (ko) 1984-03-14 1985-03-12 N-아실 인돌류 활성성분의 용해방법

Country Status (12)

Country Link
US (1) US4794117A (ko)
EP (1) EP0173729B1 (ko)
JP (1) JPS61501566A (ko)
KR (1) KR930000029B1 (ko)
AT (1) ATE57472T1 (ko)
AU (1) AU573321B2 (ko)
DE (1) DE3580140D1 (ko)
HU (1) HU195918B (ko)
IT (1) IT1200410B (ko)
NO (1) NO165626C (ko)
OA (1) OA08170A (ko)
WO (1) WO1985004106A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607662D0 (en) * 1986-03-27 1986-04-30 Rainsford K D Pharmaceutical formulation
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
FI94924C (fi) * 1987-09-11 1995-11-27 Syntex Inc Menetelmä antimikrobisesti vaikuttavan säilytyssysteemin valmistamiseksi oftalmologisesti hyväksyttäviä lääkeaineita varten
WO1991001718A1 (fr) * 1989-08-03 1991-02-21 Eisai Co., Ltd. Procede de photostabilisation pour collyre liquide et collyre liquide photostabilise
US5290774A (en) * 1989-08-03 1994-03-01 Eisai Co., Ltd. Photostabilizing method for ophthalmic solutions and the resulting ophthalmic solutions therefrom
DE4342907A1 (de) * 1993-12-16 1995-06-22 Bayer Ag Neue cyclische Depsipeptide mit 18 Ringatomen und ihre Verwendung zur Bekämpfung von Endoparasiten
PL181244B1 (pl) * 1994-09-01 2001-06-29 Upjohn Co Jałowa wodna kompozycja farmaceutyczna do stosowania pozajelitowego
US6274592B1 (en) * 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) * 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10030345A1 (de) * 2000-06-20 2002-01-10 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
ITMI20012135A1 (it) 2001-10-16 2003-04-16 Bioren S A Soluzioni iniettabili pronte all'uso di paracetamolo
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US8992980B2 (en) * 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
FR2851164B1 (fr) 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
CA2623201A1 (en) * 2005-09-30 2007-04-12 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing meloxicam
CN101909601B (zh) * 2008-01-18 2013-06-26 陶氏环球技术公司 使用甲氧基聚乙二醇增强难溶性活性剂的水溶解度的方法
KR20110116194A (ko) * 2009-02-03 2011-10-25 선스타 가부시키가이샤 헤스페리딘 함유 조성물
EP2488145B1 (en) 2009-10-12 2024-04-24 Boehringer Ingelheim Vetmedica GmbH Containers for compositions comprising meloxicam
US20110218191A1 (en) * 2010-03-03 2011-09-08 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long term-treatment of kidney disorders in cats
KR20130037237A (ko) 2010-03-03 2013-04-15 베링거잉겔하임베트메디카게엠베하 고양이에서 근골격계 장애를 장기간 치료하기 위한 멜록시캄의 용도
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
CA2805656A1 (en) * 2010-07-21 2012-01-26 Alcon Research, Ltd. Pharmaceutical composition with enhanced solubility characteristics
GB201321743D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1916432A1 (de) * 1969-03-31 1970-10-08 Dresden Arzneimittel Verfahren zur Herstellung von Injektionsloesungen von therapeutisch wertvollen Benzodiazepinderivaten und ihren Kombinationen mit anderen Wirkstoffen
IL33774A0 (en) * 1970-01-26 1970-03-22 Abic Ltd A water-soluble composition comprising sulfadimidine and pyrimethamine
DK138974B (da) * 1974-02-19 1978-11-27 Ciba Geigy Ag Fremgangsmåde til fremstilling af vandige oxytetracyclinopløsninger til parenteral, peroral og lokal anvendelse.
DE3006024C2 (de) * 1980-02-18 1983-08-04 Solvon Arzneimittel-Vertriebs- Und Lizenzgesellschaft Mbh, 85011 Burgthann Topisches, Indomethacin enthaltendes Arzneimittel in Salbenform

Also Published As

Publication number Publication date
JPS61501566A (ja) 1986-07-31
KR930000029B1 (ko) 1993-01-06
NO165626C (no) 1991-03-13
IT1200410B (it) 1989-01-18
WO1985004106A1 (fr) 1985-09-26
HUT38263A (en) 1986-05-28
EP0173729B1 (fr) 1990-10-17
IT8519873A0 (it) 1985-03-13
AU4064585A (en) 1985-10-11
HU195918B (en) 1988-08-29
EP0173729A1 (fr) 1986-03-12
NO854461L (no) 1985-11-08
NO165626B (no) 1990-12-03
ATE57472T1 (de) 1990-11-15
DE3580140D1 (de) 1990-11-22
AU573321B2 (en) 1988-06-02
OA08170A (fr) 1987-03-31
US4794117A (en) 1988-12-27

Similar Documents

Publication Publication Date Title
KR850700216A (ko) 활성성분을 용해시키기 위한 방법 및 이로부터 얻어진 제약 조성물
ATE47715T1 (de) Stabile salze von sam mit polyanionen.
ES2016159A6 (es) Gel acuoso a base de acido hilauronico y de acido desoxirribonucleico, utilizable en cosmetica, y procedimiento de preparacion.
ATE63220T1 (de) Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben.
KR860003013A (ko) 안정화된 피록시캄 주사용액의 제조방법
KR850006135A (ko) 안 과 액 제
KR890006644A (ko) 결정성 β-락탐 수화물
ES2023880T5 (es) Fijador para el cabello.
KR920002836A (ko) 물과 n-메틸모르폴린-n-옥사이드에 녹인 셀룰로오스 용액
IE40663L (en) Oxytetracycline solutions
KR950032201A (ko) 프라노프로펜의 안정화 방법 및 안정한 프라노프로펜 액제
NO301542B1 (no) Nye pyrazin-derivater
KR890005088A (ko) 4- 아미노피리딘 유도체 및 그의 산 부가염
DE3676335D1 (de) Auf mercaptoethansulfonsaeuren basierende pharmazeutische zusammensetzungen, organische abkoemmlinge von mercaptoethansulfonsaeuren sowie verfahren zu deren herstellung.
NO854581L (no) Fremgangsmaate for fremstilling av en vannloeselig polymer.
KR830004849A (ko) 약학적 제제의 제조방법
ATE162188T1 (de) Herstellung von derivaten von n-acetyl neuraminicsäure
KR910005846A (ko) 치약 조성물
KR910021361A (ko) 항궤양 물질
KR850008278A (ko) 니카르디핀 염산염의 주사용 제제의 제조방법
KR910019605A (ko) 항진균성 겔제
KR860002269A (ko) 비경구용 액제의 제조방법
KR910000154A (ko) 안정화된 피록시캄 주사액조성물과 그 제조방법
KR910004668A (ko) 해파린상 구조를 지닌 물질 및 이의 제조방법
BE901681A (fr) Rodenticides a base de derives de la phenylpropargylamine.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19851114

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19900312

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19851114

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19920526

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19921130

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19930323

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19930329

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19930329

End annual number: 3

Start annual number: 1

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee